Novavax Covid-19 vaccine shows overall efficacy of 90.4% across phase 3 trials in US/Mexico

American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the United States and Mexico. While the additional analyses of the trial are ongoing, the data would be submitted to peer-reviewed journals for publication. The trial results […]